BMS113
antibody from Invitrogen Antibodies
Targeting: CD44
CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1
Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BMS113 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD44std Monoclonal Antibody (SFF-2), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: BMS113 specifically recognizes human standard CD44, but cannot be used to distinguish between splice variants (exon v3-v10).
- Antibody clone number
- SFF-2
- Concentration
- 1 mg/mL
Submitted references Hyaluronidase reduces human breast cancer xenografts in SCID mice.
Shuster S, Frost GI, Csoka AB, Formby B, Stern R
International journal of cancer 2002 Nov 10;102(2):192-7
International journal of cancer 2002 Nov 10;102(2):192-7
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 3 Staining of xenograft breast tumor sections. Tumors were obtained from SCID mice bearing human tumors derived from the breast carcinoma cell line MDA435. Sections were stained for HA, CD44s and CD44 variant v7-8. Tumors were harvested on Day 12 after the start of hyaluronidase treatment. Treatment consisted of 4 i.v. injections of 75 rTRU of hyaluronidase on Days 0, 2, 4 and 6. Histolocalization of HA using the biotinylated hyaluronan-binding peptide in ( a ) untreated mice with mock inoculation and ( b ) after hyaluronidase treatments. Immunolocalization of CD44s using monoclonal antibodies in ( c ) untreated mice and ( d ) after hyaluronidase treatment. Immunolocalization of CD44 variant v7-8 in ( e ) untreated mice and ( f ) after hyaluronidase treatment. Magnification = x200.